Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Long-Term Investments came in at $14.7 million in Q1 2026, down 54.3% YoY from $32.2 million in Q1 2025, and down 2.41% on a QoQ basis from $15.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 6 years of Long-Term Investments data on file, last reported at $14.7 million in Q1 2026.
- Quarterly Long-Term Investments fell 54.3% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (down 54.3% YoY) and the FY2025 annual result came in at $15.1 million, down 69.07% from the prior year.
- Long-Term Investments eased to $14.7 million in Q1 2026, from $15.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $103.0 million in Q1 2022 to a low of $1.1 million in Q2 2023.
- A 5-year average of $44.0 million and a median of $32.7 million in 2025 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments surged 18274.13% — and 2023, when it slumped 98.85%.
- Tracing DNA's Long-Term Investments over 5 years: stood at $1.5 million in 2022, then jumped by 4991.7% to $78.6 million in 2023, then slumped by 38.01% to $48.7 million in 2024, then tumbled by 69.07% to $15.1 million in 2025, then slipped by 2.41% to $14.7 million in 2026.
- The last three Long-Term Investments figures came in at $14.7 million (Q1 2026), $15.1 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 14.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.78 Mn |
| Mar 31, 2026 | 14.70 Mn |
| Dec 31, 2025 | 15.07 Mn |
| Sep 30, 2025 | 30.18 Mn |
| Jun 30, 2025 | 32.66 Mn |
| Mar 31, 2025 | 32.17 Mn |
| Dec 31, 2024 | 48.70 Mn |
| Sep 30, 2024 | 62.10 Mn |
| Jun 30, 2024 | 62.49 Mn |
| Mar 31, 2024 | 76.02 Mn |
| Dec 31, 2023 | 78.57 Mn |
| Sep 30, 2023 | 84.97 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 1.54 Mn |
| Sep 30, 2022 | 96.31 Mn |
| Jun 30, 2022 | 6.91 Mn |
| Mar 31, 2022 | 103.03 Mn |
| Dec 31, 2021 | 13.19 Mn |
| Sep 30, 2021 | 16.36 Mn |